Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Morphic Holding, Inc. MORF
$57.02
-$0.48 (-0.83%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
2293006840.00000000
-
week52high
59.54
-
week52low
19.23
-
Revenue
70808000
-
P/E TTM
-35
-
Beta
1.14552600
-
EPS
-1.74000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 авг 2023 г. в 12:30
Описание компании
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wells Fargo | Overweight | Overweight | 04 авг 2022 г. |
| RBC Capital | Outperform | Outperform | 04 авг 2022 г. |
| SVB Leerink | Outperform | 20 июл 2022 г. | |
| Wells Fargo | Overweight | Overweight | 05 мая 2022 г. |
| Canaccord Genuity | Buy | 31 мар 2022 г. | |
| Stifel | Buy | 07 сент 2022 г. | |
| RBC Capital | Outperform | Outperform | 03 ноя 2022 г. |
| Wells Fargo | Overweight | Overweight | 08 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Tipirneni Praveen P. | A | 37500 | 12500 | 14 янв 2023 г. |
| Tipirneni Praveen P. | D | 12679 | 4027 | 14 янв 2023 г. |
| Tipirneni Praveen P. | A | 16706 | 12500 | 14 янв 2023 г. |
| SCHEGERIN MARC | A | 14070 | 4690 | 14 янв 2023 г. |
| SCHEGERIN MARC | D | 16212 | 1670 | 14 янв 2023 г. |
| SCHEGERIN MARC | A | 17882 | 4690 | 14 янв 2023 г. |
| Rogers Bruce | A | 15210 | 5070 | 14 янв 2023 г. |
| Rogers Bruce | D | 116192 | 1778 | 14 янв 2023 г. |
| Rogers Bruce | A | 117970 | 5070 | 14 янв 2023 г. |
| Farrell Robert E Jr | A | 10410 | 3470 | 14 янв 2023 г. |
Новостная лента
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
GlobeNewsWire
12 мая 2023 г. в 08:30
WALTHAM, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in a Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023.
3 Biotech Buyout Targets to Watch
The Motley Fool
29 апр 2023 г. в 08:25
89bio's stock is up more than 21% this year. Karuna Therapeutics says it plans to file an NDA for its lead therapy this year.
Morphic: Positive Phase 2a UC Trial, Top M&A Candidate In 2023
Seeking Alpha
25 апр 2023 г. в 22:20
Morphic: Positive Phase 2a UC Trial, Top M&A Candidate In 2023.
Morphic Holding, Inc. (MORF) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
25 апр 2023 г. в 09:53
Morphic Holding, Inc. (MORF) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.85 per share a year ago.
Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last?
Zacks Investment Research
18 апр 2023 г. в 05:22
Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.